- Home
- Automated
- List of product information
- REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML [SIN16197P]
REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML [SIN16197P]
Active ingredients: REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML
Last updated 26 October 2025
On this page
Product Info
REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML
[SIN16197P]
Product information
Active Ingredient and Strength | AGALSIDASE ALFA - 1 MG/ML |
Dosage Form | INFUSION, SOLUTION CONCENTRATE |
Manufacturer and Country | VETTER PHARMA-FERTIGUNG GMBH & CO. KG (BULK PRODUCTION AND PRIMARY PACKAGER) - GERMANY |
Registration Number | SIN16197P |
Licence Holder | TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | A16AB03 |
4.1 Therapeutic indications
Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
4.2 Posology and method of administration
Replagal treatment should be supervised by a physician experienced in the management of patients with Fabry Disease or other inherited metabolic diseases.
Posology
Replagal is administered at a dose of 0.2 mg/kg body weight every other week by intravenous infusion over 40 minutes.
Special populations
Elderly patients
Studies in patients over the age of 65 have not been performed and no dosage regimen can presently be recommended in these patients as safety and efficacy have not yet been established.
Patients with hepatic impairment
No studies have been performed in patients with hepatic impairment.
Patients with renal impairment
No dose adjustment is necessary in patients with renal impairment.
The presence of extensive renal damage (eGFR <60mL/min) may limit the renal response to enzyme replacement therapy. Limited data are available in patients on dialysis or post-kidney transplantation, no dose adjustment is recommended.
Paediatric Population
The safety and efficacy of Replagal in children aged 0–6 years has not yet been established. Currently available data are described in section 5.1 but no recommendation on posology can be made – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
In clinical studies of children (7–18 years) who received Replagal 0.2 mg/kg every other week, no unexpected safety issues were encountered (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Method of administration
For instructions on dilution of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Administer the infusion solution over a period of 40 minutes using an intravenous line with an integral filter.
Do not infuse Replagal concomitantly in the same intravenous line with other agents.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.